No Data
The biopharmaceutical industry has been positioned as an emerging pillar industry, with significant gains seen in the Sci-Tech Innovation Drug ETF, Hang Seng Innovation Drug ETF, Hong Kong Stock Connect Innovation Drug ETF, and Hong Kong Innovation Drug E
Pharmaceutical stocks in the Hong Kong stock market rose, with Guotai's Sci-Tech Innovation Drug ETF, Huitianfu's Sci-Tech Innovation Drug ETF, and Hengsheng's Innovation Drug ETF increasing by more than 4%. ICBC's Stock Connect Innovation Drug ETF, Jia Shi's Stock Connect Innovation Drug ETF, Boshi's Hong Kong Stock Innovation Drug ETF, E Fund's Stock Connect Innovation Drug ETF, NSSF's Stock Connect Innovation Drug ETF, Huitianfu's Hengsheng Biotechnology ETF, Invesco's Hong Kong Stock Innovation Drug ETF, and Wanji's Stock Connect Innovation Drug ETF also showed gains.
BOCOM International: The pharmaceutical sector is expected to maintain a stable and positive trend this year, with long-term optimism for the innovation-driven theme.
The bank recommends continued attention to the subsequent sales growth of newly included varieties/indications in medical insurance, as well as the actual implementation and payment status of commercial insurance.
ETF afternoon review | The solar energy sector exploded, with the Solar 50 ETF, Leading Solar ETF, and HT-PB CSI PTVT IDT ETF all rising over 5%.
On July 8, Gelonghui reported that the three major A-share indices rose collectively in the morning. By the time of the midday break, the Shanghai Composite Index was up 0.58%, the Shenzhen Component Index was up 1.27%, the GEM Index was up 2.25%, and the Northern Exchange 50 Index was up 1.15%. The total transaction amount in the All Market for half a day was 885.3 billion yuan, an increase of 102.3 billion yuan compared to the previous day. Over 3,900 stocks in the All Market rose. In terms of sectors, photovoltaic equipment, PCB, computing hardware, games, Consumer Electronics, and building materials saw the largest gains, while insurance, China Shipbuilding Group, Bank, electricity, and controlled nuclear fusion sectors lagged behind. In the ETF market, there was a massive surge in the photovoltaic sector, with the Cathay Fund Photovoltaic 50 ETF.
Several Hong Kong stocks of the CSI Health Care ETF fell over 2%.
On March 21, Gelonghui reported that the Hong Kong stock pharmaceutical Sector led the market decline, with several ETFs falling over 2%. The GF CSI Hong Kong Innovative Drugs Industry ETF fell 3.05%, the Yinhua National Index Hong Kong Stock Connect Innovative Drugs ETF fell 2.96%, the Huitianfu National Index Hong Kong Stock Connect Innovative Drugs ETF fell 2.85%, and the Invesco Great Wall CSI Hong Kong Stock Connect Innovative Drugs Industry ETF fell 2.73%.
Net purchases of nearly 10 billion dollars! What do you smell when mainland capital is rushing to raise Hong Kong stocks on a large scale?
Mainland capital is wantonly scavenging Hong Kong stocks.
ETF Afternoon Review丨The innovative drug sector plummeted, and Hong Kong-stock pharmaceutical ETFs fell more than 3%
On August 2, the three major A-share indices were slightly adjusted in early trading. As of midday trading, the Shanghai index fell 0.84%, the Shenzhen index fell 0.42%, and the GEM index fell 0.27%. The half-day turnover of the Shanghai and Shenzhen markets was 539.6 billion yuan. More than 3,300 stocks in the two markets fell, and Northbound Capital sold a net sale of 3.486 billion yuan in half a day. In terms of sector topics, superconductivity concepts, PET copper foil, and real estate development registered the highest gains, while China Shipbuilding, Steel, and innovative drugs registered the highest declines. In terms of ETFs, the real estate sector registered the highest gains, with Huaxia Fund's real estate ETF fund and China Southern Fund's real estate ETF rising 1.67% and 1.44% respectively.